Amyloid hypothesis takes first hit in an Alzheimer’s prevention setting

With Novartis and Amgen’s decision to halt a pair of trials in presymptomatic Alzheimer’s patients Thursday, what was widely considered the only setting left for the amyloid hypothesis in the disease took a blow.

Amyloid-lowering agents have failed at least

Read the full 393 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE